(Reuters) -Merck and Eisai’s experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived without their disease progressing, in a late-stage study, the drugmakers said on Tuesday.
However, the combination of Merck’s Welireg and Eisai’s Lenvima failed to meet the second main goal of showing statistical significance in extending overall survival, which measures the length of time patients live after diagnosis or start of treatment.
The companies plan to test overall survival at a subsequent analysis.
The combination was tested in patients whose cancer has progressed on or after treatment with immunotherapy.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
Brought to you by www.srnnews.com
